This is a first-in-human, Phase 1/2 open-label, multi-center, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
This study is being conducted in three parts:
- Part A: Phase 1 Monotherapy Dose Escalation (SNS-101 alone)
- Part B: Phase 1 Combination Dose Escalation (SNS-101 in combination with cemiplimab)
- Part C: Phase 2 Expansion Cohorts (SNS-101 alone or in combination with cemiplimab)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.